Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.B1 (
angiotensin-converting enzyme 2
)
1,025
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study is to investigate the role of
angiotensin-converting enzyme 2
(
ACE2
) in
gallbladder cancer
(GBC) and the therapeutic potential of angiotensin receptor blocker in GBC. Human gallbladder epithelial cells (HGBEC) together with GBC cells and tissue samples were used. In vitro studies were carried out to investigate the role of
ACE2
in GBC cells.
ACE2
levels were studied in in vivo GBC mouse models subject to ARB treatment.
ACE2
level was decreased in GBC cells compared with that in normal gallbladder cells. Replenishment of angiotensin II (A2) promoted tumour cell growth, which could be mitigated by
ACE2
supplement. ARB blocked A2-induced GBC cell growth and activated ERK. Activity of mTOR was not altered with different
ACE2
status. ARB inhibited tumour growth in xenograft mouse models. In vivo study also showed that decreased expression of
ACE2
was associated with enlarged tumour size. By genetic replenishment of
ACE2
and pharmaceutical use of ARB, restored
ACE2
level mitigated GBC growth. Our results supported the rationale for the use of ARB in GBC patients for potential therapeutic benefit.
...
PMID:Loss of angiotensin-converting enzyme 2 promotes growth of gallbladder cancer. 2566 64
